PTPN23 is a His-domain protein-tyrosine phosphatase implicated in ciliogenesis, the endosomal sorting complex required for transport (ESCRT) pathway, and RNA splicing. Until recently, no defined human phenotype had been associated with alterations in this gene. We identified and report a cohort of seven patients with either homozygous or compound heterozygous rare deleterious variants in PTPN23. Combined with four patients previously reported, a total of 11 patients with this disorder have now been identified. We expand the phenotypic and variation spectrum associated with defects in this gene. Patients have strong phenotypic overlap, suggesting a defined autosomal recessive syndrome caused by reduced function of PTPN23. Shared characteristics of affected individuals include developmental delay, brain abnormalities (mainly ventriculomegaly and/or brain atrophy), intellectual disability, spasticity, language disorder, microcephaly, optic atrophy, and seizures. We observe a broad range of variants across patients that are likely strongly reducing the expression or disrupting the function of the protein. However, we do not observe any patients with an allele combination predicted to result in complete loss of function of PTPN23, as this is likely incompatible with life, consistent with reported embryonic lethality in the mouse. None of the observed or reported variants are recurrent, although some have been identified in homozygosis in patients from consanguineous populations. This study expands the phenotypic and molecular spectrum of PTPN23 associated disease and identifies major shared features among patients affected with this disorder, while providing additional support to the important role of PTPN23 in human nervous and visual system development and function.
The wider application of genomic sequencing technologies, either through whole genome or whole exome sequencing (WES), has enabled the study and molecular characterization of many disorders not previously described. Genomic sequencing of cohorts of patients with shared major clinical features, such as developmental disorders , intellectual disability and developmental delay, brain malformations , congenital heart disease , or pulmonary hypertension  has successfully identified causative genes, while at the same time demonstrating the genetic heterogeneity of these broadly defined disorders. Furthermore, novel genes associated with such disorders may be identified in these cohorts; however, burden of evidence can be challenging for new candidate genes if only one patient is identified with potentially disease causing variants in a yet unreported disease gene. Ideally, evidence in support of a novel gene-disease association can be attained by identifying additional patients with overlapping clinical features and the same or functionally similar variants in the novel candidate disease gene, while further defining the phenotypic spectrum of such novel rare disorders.
PTPN23 encodes the 1636 amino acid non-receptor protein tyrosine phosphatase type 23 that appears to be essential for endocytic trafficking. It interacts with ESCRT (endosomal sorting complex required for transport) complexes to sort ubiquitinated proteins into multi-vesicular bodies (MVBs) [5, 6]. Depletion of the protein has been shown to cause accumulation of ubiquitinated proteins in the endosomes and disrupt the morphogenesis of MVBs . PTPN23 has been proposed as a tumor suppressor gene due to its apparent role in cell migration and proposed role in negatively regulating RAS mediated mitotic proliferation through its catalytically inactive C-terminal protein-tyrosine phosphatase (PTP) domain, independently from any PTP activity [7,8,9]. Finally, it appears to be important for the endurance of the survival of motor neuron (SMN) complex by maintaining its phosphorylation . In mice, PTPN23 appears to be essential for embryogenesis, with embryonic lethality occurring at around E9.5, and significant abnormalities and smaller size observed at E8.5 in homozygous knock out embryos (Ptpn23−/−) . During early embryonic development, it is predominantly expressed in the nervous system, especially in the mid and hindbrain, the optic and otic vesicles, and the ventricular layer of the forebrain. As development progresses, PTPN23 expression becomes broader, with some detectable expression across most organs [9, 11]. In adult mice, PTPN23 continues to be expressed in several brain regions including the cerebral cortex, the thalamus, and the hypothalamus . In addition, it has been shown that the Drosophila orthologue of PTPN23, Myopic (mop), is involved in neuronal specification and central nervous system development in this organism . Myopic has been shown to regulate neuropeptide secretion in the neuromuscular junction of the fly by selectively participating in the exocytosis of neuropeptide containing synaptic dense-core vesicles (DCVs) without affecting the release of small-molecule neurotransmitters from small synaptic vesicles (SSVs) .
Until recently, protein altering variants in PTPN23 had not been linked with any described human phenotype. In 2015, Alazami et al. reported PTPN23 as one of 69 novel recessive candidate genes identified through WES of multiplex consanguineous families segregating neurogenetic disorders . In 2016, Trujillano et al. identified a second patient with a rare homozygous variant in PTPN23 within a cohort of 1000 families . More recently, Sowada et al.  and Smigiel et al. , separately reported two unrelated affected female probands with compound heterozygous variants in this gene. Here, we report an additional seven patients with biallelic rare variants in PTPN23 identified through WES analyses and multi-center international collaboration. The molecular and clinical characterization of this cohort confirms the gene-disease association of PTPN23 with a severe neurodevelopmental disorder characterized by developmental delay and structural brain abnormalities, and expands the range of clinical features that may be observed in patients with this novel rare genetic disorder.
Subjects and methods
Patients and family members included in this report were consented for genetic and genomic studies, publication of clinical and genotype data, and photography through Institutional Review Board (IRB) approved protocols of the corresponding institutions. Patients are numbered according to their age at evaluation.
Patients and molecular studies
Proband 1 was evaluated at Children’s National Medical Center (CNMC) in Washington, DC, USA. Previous testing included chromosomal microarray that revealed a 15q11.2 BP1-BP2 microdeletion (Table 1). This 512 kb deletion is common (seen in about 1% of patients in whom a microarray is obtained for neurological problems), has low penetrance of about 10% , and was deemed to possibly explain only his developmental delay, but not the rest of his multisystemic phenotype. Parental testing was not obtained, although it is known that ~50% of all cases with this microdeletion inherited it from a parent with no known health or learning problems . Exome sequencing was performed through a commercial laboratory (Baylor Miraca Genetics Laboratories).
Probands 2 and 4 are from unrelated families and were evaluated at the Children’s Hospital of Eastern Ontario (CHEO) in Canada. Proband 2 had clinical exome sequencing performed through GeneDx. Proband 4 had chromosomal microarray analysis that was non-informative except for multiple regions of absence of heterozygosity (AOH) consistent with consanguinity in the family. Clinical exome sequencing for proband 4 was performed as a singleton through GeneDx.
Proband 3 was evaluated at Ochsner Medical Center in Jefferson, Louisiana, USA. He had uninformative chromosomal microarray analysis and fragile X testing. Clinical exome sequencing was performed through GeneDx.
Proband 5 was evaluated at Schneider’s Children Medical Center (SCMC) in Israel. Previous testing included normal 46XX karyotype and chromosomal microarray. Proband was also tested for Williams-Beuren Syndrome (WBS), which was negative. Research-based trio whole exome sequencing in the affected child and unaffected parents was performed in collaboration with the Regeneron Genetics Center (RGC) and analyzed as previously described .
Proband 6 was evaluated at Greenwood Genetic Center (GGC) in Greenwood, South Carolina, USA. Chromosomal microarray analysis was performed and showed a 440 kb gain variant of unknown significance (Table 1). This copy gain is within the common 15q13.3 micro-duplication/deletion region encompassing CHRNA7, mapping between breakpoints 4 and 5. Common 15q13.3 microduplications involving the CHRNA7 gene are suggested to be of uncertain clinical significance  and incompletely penetrant . Follow-up qPCR studies demonstrated maternal inheritance of this micro-duplication CNV. Other negative results included Rett and Prader-Willi/Angelman syndromes testing.
Proband 7 was evaluated at the Duke Institute for Brain Sciences (DIBS) in Durham, North Carolina, USA. Previous molecular testing included normal 46XY karyotype, muscular dystrophy panel, and Prader-Willi/Angelman syndrome FISH testing. Biochemical studies included normal amino acids, urine organic acids, lactate, pyruvate, and acylcarnitine profiles. Clinical exome sequencing was also performed through GeneDx.
Exome sequencing and variant analysis methods
Proband 1 had clinical exome sequencing performed by Baylor Miraca Genetics Laboratories. The methodology employed for exome sequencing was as follows: genomic DNA was fragmented by sonication and ligated to Illumina multiplexing paired-end adapters. For exome target enrichment and capture, the pre-capture library was hybridized in solution to the VCRome 2.1 target probes. Sequencing was performed on the Illumina HiSeq platform for 100 bp paired-end reads to achieve at least >70% of reads aligned to target, and >95% of target bases covered at >20× with a mean coverage >100×. Sequence data was aligned to the GRCh37 (hg19) human genome reference sequence. Variants were interpreted according to the American College of Medical Genetics (ACMG) guidelines and patient phenotypes.
Probands 2, 3, 4, and 7 had clinical exome sequencing through GeneDx as follows. Using genomic DNA from the proband and parents (when available), the exonic regions and flanking splice junctions of the genome were captured using the SureSelect Human All Exon V4 (50 Mb), the Clinical Research Exome kit (Agilent Technologies, Santa Clara, CA) or the IDT xGen Exome Research Panel v1.0. Massively parallel (NextGen) sequencing was done on an Illumina system with 100 bp or greater paired-end reads. Reads were aligned to human genome build GRCh37/UCSC hg19 and analyzed for sequence variants using a custom-developed analysis tool. Additional sequencing technology and variant interpretation protocol has been previously described . The general assertion criteria for variant classification are publicly available on the GeneDx ClinVar submission page (http://www.ncbi.nlm.nih.gov/clinvar/submitters/26957/). Candidate variants were confirmed by Sanger dideoxynucleotide sequencing.
For patient 5, exome capture was performed using the IDT xGen reagent (Integrated DNA Technologies, Coralville, IA, USA) and sequenced on the Illumina HiSeq 2500 platform using v4 chemistry (Illumina, San Diego, CA, USA) to achieve a minimum of 85% of the target bases covered at 20× or greater coverage. Sequence data was mapped and aligned to the human genome reference assembly GRCh38 (hg38). Called variants were annotated for their functional effects and predictions, conservation, and allele frequency in public and internal population databases. Standard quality control filters were applied for read depth (≥10×), genotype quality (≥30), and allelic balance (≥20%). Variants were filtered to exclude common, likely benign variants present in population databases (MAF ≤ 1%) and prioritized based on functional effect, deleteriousness potential, and inheritance pattern and segregation.
For patient 6, clinical whole exome sequencing was performed using the SureSelectXT Clinical Research Exome (CRE) capture kit (Agilent Technologies, Santa Clara, CA) and sequenced using an Illumina NextSeq 500® Sequencing System (Illumina Inc., San Diego, CA) per the manufacturer’s protocol. Sequences were processed using NextGENe software (SoftGenetics, LLC, State College, PA), and mapped to the February 2009 human reference assembly (GRCh37/hg19). Variants in the coding regions of the reference (and within 25 bp flanking) were retained if they had a read depth of >3× and a variant allele frequency of ≥20%. Variants were filtered and analyzed using the Cartagenia Bench Lab NGS software (Agilent Technologies, Santa Clara, CA). Variants not in the Human Genome Mutation Database (QIAGEN, Germantown, MD) were filtered based on population frequency in public SNP databases, functional effect prediction, and HPO phenotype. Quality and allele frequency filters were used to isolate variants with at least 20× read depth and 22% minor allele frequency. Candidate variants were confirmed by Sanger dideoxynucleotide sequencing.
All identified variants reported here have been deposited under submission ID SUB5492409 (accession numbers SCV000927107 through SCV000927118) for public access through ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/).
Through a combination of genomic sequencing studies, community data sharing , and multi-institutional collaboration, we have identified and characterized the largest cohort of patients with biallelic disease causing variants in the PTPN23 gene. The major clinical features in these patients are summarized below and in Table 1.
Proband 1 is a male child that presented for clinical evaluation at CNMC at 14 months of age due to developmental and motor delay. Gross and fine motor skills at 12.5 months corrected age were at 9 months. Brain MRI showed mild to moderate ventriculomegaly and enlarged subarachnoid spaces with communicating external hydrocephalus and mild decrease in cerebral volume; myelination was observed to be appropriate for age (Fig. 1A1 and A2). Proband also showed dysmorphic features including a flat occiput with brachycephaly, metopic ridging, left esotropia, arched eyebrows, and mild micrognathia. He had deep palmar creases with palmar pads, tracheoesophageal fistula, and mild left pelviectasis. WES analyses identified compound heterozygous missense variants (NM_015466.4:c.[2680 C > T];[2747 A > G], p.[(His894Tyr)];[(Gln916Arg)]) in PTPN23. Sanger confirmation and segregation showed that he had inherited the p.(His894Tyr) variant from his unaffected heterozygous father and the p.(Gln916Arg) variant from his unaffected heterozygous mother (Supplementary Material). Although these two missense variants appear to have low functional prediction scores using common in silico algorithms, both variants have high conservation scores in vertebrates and are very rare in available population cohorts (Table 2). The p.(His894Tyr) variant has been observed in 1 heterozygous individual in gnomAD (MAF = 0.000004206), whereas the p.(Gln916Arg) substitution has been observed in 8 heterozygotes in gnomAD (MAF = 0.00003382), with no reported homozygotes for either variant. Comparison of the clinical and radiological features, namely ventriculomegaly and decreased cerebral volume, in Proband 1 with other individuals identified with disease causing variants in PTPN23 in this report and in the literature further strengthened the likely diagnosis of PTPN23-associated disorder. However, the possibility of an alternative diagnosis cannot be completely excluded until further experimental evidence is provided for the PTPN23 variants identified.
Proband 2 is a male child evaluated at 2.5 years of age at CHEO. He was late to walk independently (~18 months) and remains very clumsy with bilateral intention tremor and shuffling gait at times, but not wide based. Speech was delayed with about 30 words at time of evaluation. He had an abnormal EEG (frequent isolated right parietal spike discharges) without overt seizures. Brain MRI performed at 2 years of age showed diffuse enlargement of the cerebral sulci and ventricular system which was suspicious for brain volume loss with prominent perivascular spaces (Fig. 1B2 and B3). He was short for his age, albeit not significantly (height: 89.5 cm; 15%, Z = −1.03). He had a prominent forehead and his palpebral fissures appeared subjectively short, but they were not formally measured. He had a prominent nasal root and a smooth philtrum with a thin upper lip, and low set ears that are somewhat simple, protruding, and cupped (Fig. 1B1). Hands and feet were unremarkable. He has a hypopigmented area ~4 cm in diameter on the left side of his neck that is best observed with a Woods lamp. Cardiorespiratory exam was normal. At 4.5 years of age he attends speech and occupational therapy at CHEO. Reportedly, his tremor significantly impacts his ability to feed himself and perform other fine motor tasks. Speech development has not improved significantly despite intensive therapy; he uses an iPad with communication software to indicate his basic needs. He does not appear to have any visual complaints; however no formal evaluation has been performed by an ophthalmologist. He has not developed seizures. Clinical WES identified compound heterozygous variants in PTPN23, a missense (NM_015466.4:c.3748 G > A, p.(Glu1250Lys)) variant inherited from his unaffected father and an in-frame deletion (NM_015466.4:c.2878_2889del12, p.(Gln960_Pro963del)) that was inherited from his unaffected mother (Supplementary Material). The maternally inherited in-frame deletion variant is novel and has not been previously reported, while the missense p.(Glu1250Lys) variant inherited from the father has been observed in 21 heterozygotes in gnomAD but no homozygotes (MAF = 0.00007454) (Table 2). This missense variant affects a highly conserved amino acid residue and is predicted to be deleterious by multiple bioinformatic algorithms (Fig. 2, Table 2).
Proband 3 is a male individual evaluated at Ochsner Medical Center at 6 years of age. He presented with developmental delay, intellectual disability, autism spectrum disorder, and apraxia. He had a history of ventricular septal defect and patent ductus arteriosus. He was noted to have speech dyspraxia, hyperlexia, and a sensory processing disorder. He is mildly dysmorphic with synophrys, a broad and flat nasal bridge, and full lips (Fig. 1c). He had an unremarkable brain MRI and unremarkable selective spectroscopy of the brain. Clinical exome sequencing identified compound heterozygous missense variants in PTPN23 (NM_015466.4:c.[1291 C > T];[2486 C > T], p.[(Arg431Trp)];[(Pro829Leu)]). Sanger sequencing and segregation in the proband and both parents showed that the variants were in trans in the proband, having inherited the p.(Arg431Trp) variant from his unaffected heterozygous mother and the p.(Pro829Leu) from his unaffected father (Table 2, Supplementary Material).
Proband 4 was a 7-year-old female from a consanguineous Syrian family. Family history was significant for a similarly affected brother who died at 6 years of age in Syria. She had severe growth restriction; at 7 years OFC was 47 cm (−3SD), length was not measurable due to contractures, and weight was 11.1 kg (−4SD). She had spastic quadriparesis, scoliosis, and multiple large and small joint contractures. She was confined to a wheelchair with little purposeful movement and no head control. She had cataracts and significant visual impairment with abnormal eye movements and poor pupillary reactions to light. She had not attained language skills. She also had a history of recurrent infections and aspiration pneumonia. Dysmorphic features were notable for a long and narrow face with very prominent ears. Brain MRI was performed in Syria and results were unavailable, but parents recalled findings consistent with atrophy and possible lissencephaly. The patient passed away at 7 years of age. Exome sequencing revealed a homozygous in-frame variant in PTPN23 (NM_015466.4:c.2568_2594del27; p.(Val857_Pro865del)) that was further confirmed by Sanger sequencing (Supplementary Material). This in-frame deletion of nine amino acids of PTPN23 is novel and has not been observed in the heterozygous or homozygous state in any publicly available databases. Seven of the nine deleted amino acids are highly conserved in mammals and the variant is predicted to be deleterious for protein function. Of note, another rare homozygous variant of unknown significance in EOMES (NM_001278182.1:c.692 A > G; p.(Tyr231Cys)) was identified in linkage disequilibrium with the PTPN23 variant within the same region of homozygosity.
Proband 5 is a 10-year-old female from an Ashkenazi Jewish family from Israel. She was evaluated at SCMC due to developmental delay and mild intellectual disability. She has difficulty with social interactions. Brain MRI showed insular and parietoocipital polymicrogyria with partial agenesis of the corpus callosum and hypoplasia of the optic nerves. She was noted to be different in appearance to her parents with dysmorphic features including a long face, prominent forehead, malar hypoplasia, a long and smooth philtrum, a broad and long mouth with full lips, hypoplasia of ala nasi, anteverted nares, bulbous nasal tip, low-hanging collumela, posteriorly rotated ears, and narrow and high-arched palate (Fig. 1 D1 and D2). She had fetal fat pads and pes planus, but no skeletal abnormalities. Trio WES analysis identified a homozygous in-frame deletion of one amino acid variant (NM_015466.4: c.3884_3886delAGA; p.(1295_1296delLys)) in PTPN23 as the main candidate for the phenotype in this proband. Although this variant is an in-frame deletion of one amino acid, multiple species alignment shows that this Lysine at position 1296 of PTPN23 is extremely well-conserved, suggesting it might be relevant for the function of the protein. This variant has been previously reported and observed in 159 heterozygous individuals in gnomAD (MAF = 0.0005721) but no homozygotes. This variant is most prevalent in Ashkenazi Jewish individuals (MAF = 0.01273) consistent with the reported ancestry of this patient and her parents.
Proband 6 is a female patient of European ancestry with no reported parental consanguinity. She was evaluated at GGC due to developmental delay with regression at 2 years of age and carried a diagnosis of cerebral palsy. She is nonverbal at 11 years of age. She has microcephaly with delayed myelination and enlargement of the posterior left lateral ventricle, optic atrophy, and optic nerve hypoplasia observed on MRI. She also has spastic diplegia, hypotonia, contractures at the knees, femoral anteversion that was surgically corrected, slow gait with bent knees, and hyperreflexia with multiple beats of clonus at the ankles. Other features noted were constipation and past sleep problems that were resolved. EEG was normal and no seizure disorder was noted or reported. She was mildly dysmorphic with strabismus, thin eyebrows, prominent and wide-spaced upper incisors, broad mouth and full lips (Fig. 1E1 and E2). Narrow hands and feet were also noted. A homozygous frameshift variant (NM_015466.4:c.4651_4652dup; p.(Leu1552Hisfs*33)) in the last exon was identified in PTPN23 through trio exome sequencing. Because of its location, this frameshift variant in the last exon is expected, and further predicted through in silico methods , to escape nonsense mediated decay and result in a truncated protein product. Both parents were confirmed to be heterozygous carriers for this rare variant, which has not been reported elsewhere. Of note, this rare variant in PTPN23 was found to be embedded within a 14.3 Mb region of absence of heterozygosity (AOH) at 3p21.31p14.2 (Table 1). Total autosomal AOH for the proband was only 0.8% consistent with reported non-consanguinity of the parents; however, it is suggestive of the haplotype carrying this variant being identical by-descent in both parents.
Proband 7 is a 13-year-old Hispanic male evaluated at DIBS. He has a history of developmental delay and intellectual disability with bilateral brain atrophy observed on MRI. He has short stature, hypotonia, areflexia, neuromuscular scoliosis, and joint contractures. He had precocious puberty, central sleep apnea, and expressive language delay. He remains nonverbal. He has a history of intractable seizures that started at 2 years of age and complicated by apnea with insomnia and frequent sleep arousals. He is not particularly dysmorphic but does have strabismus. WES analysis identified three rare missense variants in PTPN23 in this proband. Two variants (NM_015466.4:c.[1748A > G; 3051 G > C], p.[(Lys583Arg); p.(Gln1017His)]) are in cis and were inherited from his unaffected mother. Both maternally inherited variants are rare, and neither could be definitely excluded; however, the p.(Gln1017His) variant is more frequent (MAF = 0.0002481) and has been observed in one homozygous individual in gnomAD. The residue being altered is also less well-conserved and the substitution is predicted to be more tolerated. Conversely, the p.(Lys583Arg) has been observed in 21 heterozygous individuals but no homozygotes in gnomAD (MAF = 0.00007427), the affected residue is highly conserved across species, and the amino acid change is predicted to be deleterious (Table 2). The proband also inherited in trans a missense (NM_015466.4:c.695 G > A; p.(Arg232Gln)) variant from his unaffected heterozygous father. This variant is also present in gnomAD (MAF = 0.00003892) but with no reported homozygous instances (Table 2).
The main clinical findings and features for the patients reported here and in the four previously reported patients are summarized in Table 1 and Fig. 1. Overall, we observe some major features shared among the majority of patients with biallelic protein altering variants in PTPN23, namely developmental delay (100%), intellectual disability (100%), brain abnormalities (91%), mostly characterized by brain atrophy with cerebral volume loss, ventriculomegaly, and delayed myelination; tone or movement disorder (82%), language absence or delay (82%), microcephaly (63%), and optic atrophy (54%). Interestingly, although seizures were one of the main findings in the initially reported patients, in our cohort this is not a consistent feature; only 2 of the 7 patients in our cohort were reported to have a history of febrile or intractable seizures, with an overall 54% of all patients reported to date having epileptic encephalopathy. Therefore, epilepsy should not be considered a cardinal clinical sign for the diagnosis of this neurodevelopmental disorder. Dysmorphic features were observed among patients including prominent forehead, deep set eyes, strabismus, prominent ears, broad and flat nasal bridge with a broad nose tip, and a broad mouth with full lips.
PTPN23 is located in chromosome 3p21.3 and is composed of 24 exons. The variation spectrum that we observe in our cohort of patients includes missense (N = 8), frameshift (N = 1), and in-frame deletion variants (N = 3) (Fig. 2). The identified missense variants occur in highly conserved residues supporting their candidacy for affecting PTPN23 function (Fig. 2c). We do not observe a clear correlation between identified protein altering variants and disease severity across our patients and the reported cases. However, some of the homozygous individuals, such as Patient 4 in this report and the first patient reported by Alazami et al. , and individuals with one predicted loss-of-function allele in trans of another non-truncating allele appear to be more severely affected. Furthermore, although in some cases compound heterozygosity for predicted loss-of-function, either nonsense or frameshift variants, in trans with rare predicted deleterious missense variants has been observed, no homozygous or compound heterozygous individuals with biallelic predicted loss-of-function variants have yet been reported by us or others. The only homozygous frameshift variant (NM_015466.4:c.[4651_4652dup]; p.(Leu1552Hisfs*33)) identified to date in our Patient 6 occurs in the last exon of the gene and it is predicted to escape nonsense mediated decay producing a smaller truncated protein product lacking the last 51 amino acids, with an aberrant C-terminal region. The absence of patients reported so far with biallelic loss-of-function variants would be consistent with the early embryonic lethality reported in homozygous knockout mice and therefore suggests that the rare missense and in-frame deletion variants identified in patients are likely hypomorphic alleles that may retain some functional activity of PTPN23 protein. Characterization of these variants at the molecular and biochemical level will help elucidate the precise functional effects on the protein. For example, Sowada et al.  performed in silico modeling of the reported variants in PTPN23 and propose that the p.(Pro532Leu) variant likely alters the structure of the protein reducing its stability and affecting its sorting function. The p.(Arg1332Leu) variant is also predicted to disrupt the structure of the protein, primarily of the PTPase domain, by destabilizing the molecular interactions of this domain with other structurally relevant amino acids and with its substrates. Finally, the p.(Met302Val) variant is predicted to have a milder effect, mostly reducing protein stability and potentially altering binding to other proteins and protein complexes . More recently, Smigiel et al.  functionally studied fibroblasts derived from their patient, carrying a predicted protein truncating variant in trans with a rare p.(Asn634Lys) missense variant. While they observed expression of the PTPN23 protein, they reported strongly reduced SMN accumulation in Cajal bodies versus increased nucleoplasmic levels of SMN in the patient derived cells compared to unaffected parent and control fibroblasts, in spite of similar SMN protein expression . Altogether, these analyses and observations support the hypothesis that disease associated variants that affect PTPN23 function are likely hypomorphic and suggest that residual PTPN23 function is necessary for human viability and early development; whereas, similarly to mouse, complete loss of function due to biallelic truncating variants in PTPN23 is likely lethal in humans.
Smigiel et al. suggest abnormal SNM phosphorylation and localization or impaired maturation of uridine-rich small nuclear ribonucleoproteins (UsnRNPs) as possible mechanisms of disease for PTPN23 protein altering variants . However, the multiple processes in which PTPN23 has been implicated suggest that defects in this gene can lead to the observed phenotype through abnormal processing and trafficking of a wider variety of protein complexes, in addition to SMN. For example, impaired ESCRT function has been associated with intracellular accumulation of ubiquitinated proteins that may aggregate in the brain and cause neuronal degeneration and microcephaly [26, 27]. In addition, PTPN23 has been nominated as a tumor suppressor candidate gene due to its apparent function in regulating cell migration and possibly autophagy . These functions could very well play a role in the structural brain abnormalities and microcephaly observed in individuals with biallelic variants in this gene that affect correct protein function.
While four patients had previously been identified and reported in the literature, the work presented here details the genetic and phenotypic analyses of the largest series of patients with biallelic disease causing variants in PTPN23, enabling characterization of this novel genetic disorder. The majority of variants identified in patients with this genetic disorder are rare or have not previously been observed in population databases. However, as exemplified by Proband 5, some variants may be rare founder alleles in certain populations, such as Ashkenazi Jewish individuals, and should be considered in screening panels for intellectual disability. We have clinically characterized seven patients and expanded the phenotypic and disease associated variation spectrum of the PTPN23 associated disorder characterized by developmental delay, intellectual disability, brain abnormalities including ventriculomegaly and brain atrophy, optic nerve abnormalities, spasticity, and variable seizures. Identification and characterization of these seven patients in the context of the previously reported patients help to further identify major clinical features and define the phenotypic spectrum of the disease. Once recognized molecularly, genotype-phenotype correlation and identification of shared clinical features can enable more accurate clinical diagnoses of this rare disorder and inform natural history of the disease for future patients.
Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. Nature. 2017;542:433–8.
Karaca E, Harel T, Pehlivan D, Jhangiani SN, Gambin T, Coban Akdemir Z, et al. Genes that affect brain structure and function identified by rare variant analyses of mendelian neurologic disease. Neuron. 2015;88:499–513.
Jin SC, Homsy J, Zaidi S, Lu Q, Morton S, DePalma SR, et al. Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. Nat Genet. 2017;49:1593–601.
Zhu N, Gonzaga-Jauregui C, Welch CL, Ma L, Qi H, King AK, et al. Exome sequencing in children with pulmonary arterial hypertension demonstrates differences compared with adults. Circ Genom Precis Med. 2018;11:e001887.
Tabernero L, Woodman P. Dissecting the role of His domain protein tyrosine phosphatase/PTPN23 and ESCRTs in sorting activated epidermal growth factor receptor to the multivesicular body. Biochem Soc Trans. 2018;46:1037–46.
Doyotte A, Mironov A, McKenzie E, Woodman P. The Bro1-related protein HD-PTP/PTPN23 is required for endosomal cargo sorting and multivesicular body morphogenesis. Proc Natl Acad Sci USA. 2008;105:6308–13.
Toyooka S, Ouchida M, Jitsumori Y, Tsukuda K, Sakai A, Nakamura A, et al. HD-PTP: A novel protein tyrosine phosphatase gene on human chromosome 3p21.3. Biochem Biophys Res Commun. 2000;278:671–8.
Cao L, Zhang L, Ruiz-Lozano P, Yang Q, Chien KR, Graham RM, et al. A novel putative protein-tyrosine phosphatase contains a BRO1-like domain and suppresses Ha-ras-mediated transformation. J Biol Chem. 1998;273:21077–83.
Gingras MC, Zhang YL, Kharitidi D, Barr AJ, Knapp S, Tremblay ML, et al. HD-PTP is a catalytically inactive tyrosine phosphatase due to a conserved divergence in its phosphatase domain. PLoS ONE. 2009;4:e5105.
Husedzinovic A, Neumann B, Reymann J, Draeger-Meurer S, Chari A, Erfle H, et al. The catalytically inactive tyrosine phosphatase HD-PTP/PTPN23 is a novel regulator of SMN complex localization. Mol Biol Cell. 2015;26:161–71.
Gingras MC, Kharitidi D, Chénard V, Uetani N, Bouchard M, Tremblay ML, et al. Expression analysis and essential role of the putative tyrosine phosphatase His-domain-containing protein tyrosine phosphatase (HD-PTP). Int J Dev Biol. 2009;53:1069–74.
Bivik C, Bahrampour S, Ulvklo C, Nilsson P, Angel A, Fransson F, et al. Novel genes involved in controlling specification of Drosophila FMRFamide neuropeptide cells. Genetics. 2015;200:1229–44.
Bulgari D, Jha A, Deitcher DL, Levitan ES. Myopic (HD-PTP, PTPN23) selectively regulates synaptic neuropeptide release. Proc Natl Acad Sci USA. 2018;115:1617–22.
Alazami AM, Patel N, Shamseldin HE, Anazi S, Al-Dosari MS, Alzahrani F, et al. Accelerating novel candidate gene discovery in neurogenetic disorders via whole-exome sequencing of prescreened multiplex consanguineous families. Cell Rep. 2015;10:148–61.
Trujillano D, Bertoli-Avella AM, Kumar Kandaswamy K, Weiss ME, Köster J, Marais A, et al. Clinical exome sequencing: results from 2819 samples reflecting 1000 families. Eur J Hum Genet. 2017;25:176–82.
Sowada N, Hashem MO, Yilmaz R, Hamad M, Kakar N, Thiele H, et al. Mutations of PTPN23 in developmental and epileptic encephalopathy. Hum Genet. 2017;136:1455–61.
Smigiel R, Landsberg G, Schilling M, Rydzanicz M, Pollak A, Walczak A, et al. Developmental epileptic encephalopathy with hypomyelination and brain atrophy associated with PTPN23 variants affecting the assembly of UsnRNPs. Eur J Hum Genet. 2018;26:1502–11.
Butler MG. Clinical and genetic aspects of the 15q11.2 BP1-BP2 microdeletion disorder. J Intellect Disabil Res. 2017;61:568–79.
Cafferkey M, Ahn JW, Flinter F, Ogilvie C. Phenotypic features in patients with 15q11.2(BP1-BP2) deletion: further delineation of an emerging syndrome. Am J Med Genet A. 2014;164A:1916–22.
Strauss KA, Gonzaga-Jauregui C, Brigatti KW, Williams KB, King AK, Van Hout C, et al. Genomic diagnostics within a medically underserved population: efficacy and implications. Genet Med. 2018;20:31–41.
Szafranski P, Schaaf CP, Person RE, Gibson IB, Xia Z, Mahadevan S, et al. Structures and molecular mechanisms for common 15q13.3 microduplications involving CHRNA7: benign or pathological? Hum Mutat. 2010;31:840–50.
Gillentine MA, Schaaf CP. The human clinical phenotypes of altered CHRNA7 copy number. Biochem Pharm. 2015;97:352–62.
Retterer K, Juusola J, Cho MT, Vitazka P, Millan F, Gibellini F, et al. Clinical application of whole-exome sequencing across clinical indications. Genet Med. 2016;18:696–704.
Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum Mutat. 2015;36:928–30.
Coban-Akdemir Z, White JJ, Song X, Jhangiani SN, Fatih JM, Gambin T, et al. Identifying genes whose mutant transcripts cause dominant disease traits by potential gain-of-function alleles. Am J Hum Genet. 2018;103:171–87.
Suzuki S, Tamai K, Watanabe M, Kyuuma M, Ono M, Sugamura K, et al. AMSH is required to degrade ubiquitinated proteins in the central nervous system. Biochem Biophys Res Commun. 2011;408:582–8.
McDonell LM, Mirzaa GM, Alcantara D, Schwartzentruber J, Carter MT, Lee LJ, et al. Mutations in STAMBP, encoding a deubiquitinating enzyme, cause microcephaly-capillary malformation syndrome. Nat Genet. 2013;45:556–62.
The authors wish to thank the patients and families that participated in this study. We also acknowledge the support of the Care4Rare Canada Consortium, funded by Genome Canada and the Canadian Institutes of Health Research (CIHR) for the investigation of Patient 4. KMB is supported by a Foundation grant from CIHR (FDN-154279).
Conflict of interest
REP, YS, IMW, and ET are employees of GeneDx, Inc., a wholly owned subsidiary of OPKO Health, Inc. CG-J is a full-time employee of the Regeneron Genetics Center from Regeneron Pharmaceuticals Inc. and receives stock options as part of compensation. All remaining authors declare that they have no conflict of interest.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.